Vincent G Demarco
Affiliation: University of Missouri
Demarco V, Habibi J, Jia G, Aroor A, Ramirez Perez F, Martinez Lemus L, et al
. Low-Dose Mineralocorticoid Receptor Blockade Prevents Western Diet-Induced Arterial Stiffening in Female Mice. Hypertension. 2015;66:99-107 pubmed publisher
Hayden M, Grant D, Aroor A, Demarco V. Empagliflozin Ameliorates Type 2 Diabetes-Induced Ultrastructural Remodeling of the Neurovascular Unit and Neuroglia in the Female db/db Mouse. Brain Sci. 2019;9: pubmed publisher
..We conclude that these abnormalities in the NVU were prevented in DBE. Empagliflozin may provide neuroprotection in the diabetic brain. ..
Habibi J, Aroor A, Das N, Manrique Acevedo C, Johnson M, Hayden M, et al
. The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat. Cardiovasc Diabetol. 2019;18:40 pubmed publisher
..These novel findings warrant future clinical investigations designed to test whether sac/val may offer renoprotection in the setting of DN. ..
Aroor A, Das N, Carpenter A, Habibi J, Jia G, Ramirez Perez F, et al
. Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury. Cardiovasc Diabetol. 2018;17:108 pubmed publisher
..Empagliflozin ameliorates kidney injury in type 2 diabetic female mice by promoting glycosuria, and possibly by reducing systemic and renal artery stiffness, and reversing RECK suppression. ..
Demarco V, Ford D, Henriksen E, Aroor A, Johnson M, Habibi J, et al
. Obesity-related alterations in cardiac lipid profile and nondipping blood pressure pattern during transition to diastolic dysfunction in male db/db mice. Endocrinology. 2013;154:159-71 pubmed publisher
..In conclusion, a distinct pattern of myocardial lipid remodeling, accompanied by oxidative stress, is associated with the onset of diastolic dysfunction in obese, insulin-resistant db/db mice. ..
Aroor A, Manrique Acevedo C, Demarco V. The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin. Cardiovasc Diabetol. 2018;17:59 pubmed publisher
Demarco V, Habibi J, Whaley Connell A, Schneider R, Sowers J, Andresen B, et al
. Rosuvastatin ameliorates the development of pulmonary arterial hypertension in the transgenic (mRen2)27 rat. Am J Physiol Heart Circ Physiol. 2009;297:H1128-39 pubmed publisher
..These data suggest that statins may be a clinically viable adjunct treatment of PAH through reducing peroxynitrite formation. ..
Manrique C, Habibi J, Aroor A, Sowers J, Jia G, Hayden M, et al
. Dipeptidyl peptidase-4 inhibition with linagliptin prevents western diet-induced vascular abnormalities in female mice. Cardiovasc Diabetol. 2016;15:94 pubmed publisher
..Whether, DPP-4 inhibition could be a therapeutic tool used to prevent the development of aortic stiffening and the associated cardiovascular complications in obese and diabetic females remains to be elucidated. ..
Habibi J, Aroor A, Sowers J, Jia G, Hayden M, Garro M, et al
. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovasc Diabetol. 2017;16:9 pubmed publisher
..In summary, EMPA improved glycemic indices along with diastolic relaxation, as well as SGK1/ENaC profibrosis signaling and associated interstitial fibrosis, all of which occurred in the absence of any changes in BP. ..